FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.

Institutional investor · Portfolio as of Q4 2024

SEC EDGAR SourceSEC Filings

Top Holdings151 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
SPYSPY
PUT

STATE STREET SPDR S&P 500 ETF TRUST CL USD INC

4.2M$2.4B10.7%
Decreased

HESS CORP

6.4M$857.2M3.8%
5 qtrssince 2023-Q4
Unchanged
0

EXELIXIS INC

23.4M$780.5M3.4%$19.15+75.97%
25 qtrssince 2018-Q4
Decreased
0
RSPRSP
PUT

INVESCO S&P 500 EQUAL WEIGHT

4.4M$771M3.4%
Unchanged

UNITEDHEALTH GROUP INC

1.5M$739.8M3.2%$468.03+5.89%
8 qtrssince 2023-Q1
Increased
75
DFSDFSDelisted

CAPITAL ONE FINANCIAL CO

4.3M$738M3.2%
4 qtrssince 2024-Q1
Increased
94

NATERA INC

4.4M$701.5M3.1%$66.85+137.16%
15 qtrssince 2021-Q2
Decreased
0

MICROSOFT CORP

1.6M$688.4M3.0%$269.55+56.45%
25 qtrssince 2018-Q4
Increased
65

AON PLC

1.8M$658.2M2.9%$306.68+16.10%
4 qtrssince 2024-Q1
Increased
58

THERMO FISHER SCIENTIFIC INC

1.2M$641.6M2.8%$468.31+10.40%
21 qtrssince 2019-Q4
Increased
81

IQVIA HOLDINGS INC

3.1M$613.7M2.7%$170.94+15.51%
25 qtrssince 2018-Q4
Decreased
0

REVOLUTION MEDICINES INC

13.2M$579.5M2.5%$34.63+24.67%
16 qtrssince 2021-Q1
Increased
63

AUTODESK INC

1.8M$544.4M2.4%$297.530.00%
1 qtr
New
81

TRANSUNION

5.3M$493.8M2.2%$86.03+7.24%
25 qtrssince 2018-Q4
Decreased
0

WALT DISNEY CO/THE

4.4M$493.1M2.2%$96.25+13.86%
3 qtrssince 2024-Q2
Decreased
0
IBBIBB
PUT

ISHARES BIOTECHNOLOGY ETF

3.6M$476M2.1%
Increased

LANTHEUS HOLDINGS INC

5.3M$475.6M2.1%$83.36+6.92%
8 qtrssince 2023-Q1
Increased
82

INTUIT INC

753,758$473.7M2.1%$455.81+37.12%
9 qtrssince 2022-Q4
Increased
64

BOSTON SCIENTIFIC CORP

5M$448.7M2.0%$51.33+74.71%
18 qtrssince 2020-Q3
Decreased
0

ARAMARK

11.4M$425.7M1.9%$25.90+42.20%
17 qtrssince 2020-Q4
Decreased
0
$22.8B
AUM
151
Positions
Q4 2024
Filing
Rating · 1.5
Quarterly Portfolio Change
+8%Q3'23$21.4B+2%Q4'23$21.9B+8%Q1'24$23.6B-1%Q2'24$23.3B-2%Q3'24$22.8B-0%Q4'24$22.8B
Activity profile
$ moved · Q4'24
New17%Increased32%Decreased24%Exited27%
Composition
Equity vs derivatives
Equity83%Puts17%Calls0%
Holding period
Avg 2.1 years
<1Q14%1-4Q27%1-2Y18%2Y+41%

FARALLON CAPITAL MANAGEMENT, L.L.C. manages $22.8B across 151 positions as of Q4 2024. Top holdings: SPY (10.7%), HES (3.8%), EXEL (3.4%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 1.5/5.0.

Q4 2024 Summary

Active quarter - 24 new positions, 38 exits, 36 increased. Top move: DFS (INCREASED, conviction 94). Portfolio: $22.8B across 151 positions.

Top holdings by portfolio weight

Total AUM$19B
HES3.76%
EXEL3.42%
UNH3.25%
DFS3.24%
NTRA3.08%
MSFT3.02%
AON2.89%
TMO2.81%
IQV2.69%
RVMD2.54%
Other2.39%

Portfolio allocation by GICS sector

Sectors10
Healthcare40.54%
Unknown17.12%
Technology13.73%
Financial Services10.75%
Communication Services8.19%
Industrials5.23%
Consumer Cyclical1.81%
Real Estate1.81%
Consumer Defensive0.80%
Energy0.01%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown, Technology
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track Record60
Conviction43
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
8Q
CRNXCRNXCRINETICS PHARMACEUTICALS IN
Q3 2024 Q2 2026+8.5M shares+$314.1M
7Q
BBIOBBIOBRIDGEBIO PHARMA INC
Q4 2024 Q2 2026+9M shares+$755.7M
5Q
BSXBSXBOSTON SCIENTIFIC CORP
Q2 2025 Q2 2026+6.8M shares+$69.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used